Tashana Lewis
Psychiatric/Mental Health · Upland, CANPI 1497134688
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,623 and has fallen 67.8% since, to $1,167 in 2025. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 479 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Johnson & Johnson$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$919
- plus $4K from 14 others
What the payments were for
- Food & beverage$12,31699%
- Education$1501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 87 | $2,593 |
| Johnson & Johnson | 49 | $1,452 |
| AbbVie | 61 | $1,294 |
| Alkermes, Inc. | 38 | $1,081 |
| Teva Pharmaceuticals USA, Inc. | 32 | $1,017 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $919 |
| Neurocrine Biosciences, Inc. | 21 | $902 |
| Vanda Pharmaceuticals Inc. | 31 | $887 |
| Supernus Pharmaceuticals, Inc. | 27 | $664 |
| Sunovion Pharmaceuticals Inc. | 40 | $617 |
| Axsome Therapeutics, Inc. | 9 | $440 |
| Otsuka America Pharmaceutical, Inc. | 13 | $244 |
| Idorsia Pharmaceuticals US Inc | 14 | $193 |
| Janssen Scientific Affairs, LLC | 2 | $48 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Lundbeck LLC | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $15 |
| Cvrx, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$1,001
- INGREZZA$524
- LYBALVI$487
- ARISTADA$480
- VRAYLAR$376
- QELBREE$338
- Auvelity$335
- INVEGA SUSTENNA$250
- INVEGA TRINZA$250
- Austedo XR$227
- Fanapt$125
- SPRAVATO$124
- ARISTADA INITIO$120
- AUSTEDO$111
How this compares
$12,466 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 31 | $42,615 |
| Loreev XrLorazepam | 13 | $5,640 |
| Trazodone Hcl | 63 | $584 |
| Sertraline Hcl | 68 | $536 |
| Quetiapine Fumarate | 43 | $437 |
| Bupropion XlBupropion Hcl | 34 | $431 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $388 |
| Temazepam | 11 | $294 |
| Lurasidone Hcl | 15 | $264 |
| Mirtazapine | 21 | $241 |
| Olanzapine | 24 | $180 |
| Duloxetine Hcl | 26 | $177 |
| Aripiprazole | 39 | $172 |
| Gabapentin | 13 | $167 |
| Hydroxyzine Hcl | 14 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,294 | $42,61531 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $18 | $6,17581 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Upland
- Michael SolanoUpland$14K
- Percival BaldriasUpland$14K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.